ANGPT1 as a Prognostic Biomarker in a Large-Scale Pan-cancer Analysis

Angiopoietin 1 (ANGPT1) plays a significant role in tumorigenesis, prognosis, and chemoresistance across various cancers. This study demonstrated that ANGPT1 expression is heterogeneous among tumor types, with high expression linked to poor prognosis in multiple cancers and associated with immune infiltration, tumor mutation burden, and drug sensitivity. In acute myeloid leukemia (AML), ANGPT1 was markedly upregulated in patients compared to healthy controls and further elevated in non-responders versus complete remission cases. Functional assays confirmed its role in promoting AML cell proliferation, highlighting ANGPT1 as a promising prognostic biomarker and therapeutic target in AML and other malignancies. Overall design: Bone marrow mononuclear cells were collected from newly diagnosed, treatment-naïve acute myeloid leukemia (AML) patients for RNA sequencing (RNA-seq).

血管生成素1（Angiopoietin 1, ANGPT1）在多种癌症的发生发展、预后及化疗耐药中发挥关键作用。本研究显示，ANGPT1的表达在不同肿瘤类型中存在异质性：高表达与多种癌症的不良预后显著相关，同时还与免疫浸润、肿瘤突变负荷及药物敏感性存在关联。在急性髓系白血病（acute myeloid leukemia, AML）中，与健康对照相比，AML患者的ANGPT1表达显著上调；且相较于达到完全缓解的患者，治疗无应答者的ANGPT1表达进一步升高。功能实验证实其可促进AML细胞增殖，表明ANGPT1是AML及其他恶性肿瘤极具潜力的预后生物标志物与治疗靶点。实验整体设计：收集新诊断且未接受过任何治疗的急性髓系白血病患者的骨髓单个核细胞进行RNA测序（RNA-seq）。